Research graph
References from Oncofetal antigens as emerging targets in chimeric antigen receptor (CAR)-T cell-based immunotherapies: opportunities and challenges. Local targets link to admitted publications; unresolved targets remain external evidence.
Accelerating and optimising CAR T-cell manufacture to deliver better patient products
10.1016/s2352-3026(24)00273-4 · 2025 · External reference
Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development
10.1007/s004270100140 · 2001 · External reference
Analysis of ROR1 protein expression in human cancer and normal tissues
10.1158/1078-0432.ccr-16-2083 · 2017 · External reference
Killing mechanisms of chimeric antigen receptor (CAR) T cells
10.3390/ijms20061283 · 2019 · External reference
ROR1, an embryonic protein with an emerging role in cancer biology
10.1007/s13238-014-0059-7 · 2014 · External reference
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
10.1002/mco2.427 · 2023 · External reference
Pan-cancer analysis and the oncogenic role of glypican 1 in hepatocellular carcinoma
10.1038/s41598-024-66838-9 · 2024 · External reference
Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma
10.1093/jleuko/qiae144 · 2025 · External reference
GPC2 is a potential diagnostic, immunological, and prognostic biomarker in pan-cancer
10.3389/fimmu.2022.857308 · 2022 · External reference
Ror2 as a therapeutic target in cancer
10.1016/j.pharmthera.2015.01.010 · 2015 · External reference
CAR-T cells in solid tumors: challenges and breakthroughs
10.1016/j.xcrm.2025.102353 · 2025 · External reference
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
10.1038/s41571-022-00704-3 · 2023 · External reference
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
10.1038/s41591-018-0010-1 · 2018 · External reference
RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial
10.1016/j.eclinm.2023.102175 · 2023 · External reference
Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro
2002 · External reference
Hypoxia-responsive CEA-Targeted CAR T cells in CEA-Positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial
10.1038/s43018-026-01124-3 · 2026 · External reference
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers
10.1136/jitc-2023-008659 · 2024 · External reference
High prevalence of 5T4/Trophoblast glycoprotein in soft tissue sarcomas
10.3390/cancers13194841 · 2021 · External reference
GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma
10.1016/j.bbrep.2024.101741 · 2024 · External reference
Effective antitumor activity of 5T4-specific CAR-T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo
10.1002/mco2.34 · 2020 · External reference
Armored CAR T-Cells: the next chapter in T-Cell cancer immunotherapy
10.2147/btt.s291768 · 2021 · External reference
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
10.1186/s40425-017-0222-9 · 2017 · External reference
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
10.1016/j.ccell.2021.12.005 · 2022 · External reference
Anti-extra domain B splice variant of fibronectin antibody-drug conjugate eliminates tumors with enhanced efficacy when combined with checkpoint blockade
10.1158/1535-7163.mct-22-0099 · 2022 · External reference
NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors
10.1038/s41467-026-69796-0 · 2026 · External reference
Phase I study of ROR1-Specific CAR-T cells in advanced hematopoietic and epithelial malignancies
10.1158/1078-0432.ccr-24-2172 · 2025 · External reference
Carcinoembryonic antigen expression in human tumors: a tissue microarray study on 13,725 tumors
10.3390/cancers16234052 · 2024 · External reference
Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis
10.1186/1749-8104-4-33 · 2009 · External reference
GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells
10.1007/s00018-010-0292-z · 2010 · External reference
GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab
10.7554/elife.49392 · 2020 · External reference
Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor–modified T-cell therapy for CEA+ liver metastases
10.1158/1078-0432.ccr-14-1421 · 2015 · External reference
HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases
10.1038/s41417-019-0104-z · 2020 · External reference
CLDN6 expression plasticity in ovarian cancer: insights into therapeutic optimization for CLDN6-Targeted immunotherapy
10.1158/2767-9764.crc-25-0399 · 2026 · External reference
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
10.1182/blood-2010-04-281931 · 2010 · External reference
GANGLIOSIDE GD(2) EXPRESSION IN THE HUMAN NERVOUS-SYSTEM AND IN NEUROBLASTOMAS - AN IMMUNOHISTOCHEMICAL STUDY
10.3892/ijo.3.5.909 · 1993 · External reference
Tumor-associated glycoprotein (TAG-72) is a natural ligand for the C-type lectin-like domain that induces anti-inflammatory orientation of early pregnancy decidual CD1a+ dendritic cells
10.1016/j.jri.2010.10.001 · 2011 · External reference
NK-92MI cells engineered with Anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer
10.7150/ijbs.88539 · 2024 · External reference
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma
10.1038/s41591-025-03513-0 · External reference
ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2
10.1186/s40364-025-00730-0 · External reference
Emerging biomedical imaging-based companion diagnostics for precision medicine
10.1016/j.isci.2023.107277 · 2023 · External reference
Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies
10.1016/j.biopha.2024.117252 · 2024 · External reference
Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumors
10.1101/2025.09.22.677496 · 2025 · External reference
DNA methylation of claudin-6 promotes breast cancer cell migration and invasion by recruiting MeCP2 and deacetylating H3Ac and H4Ac
10.1186/s13046-016-0396-x · 2016 · External reference
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial
10.1038/s41591-025-03874-6 · 2025 · External reference
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
10.1182/bloodadvances.2020002394 · 2020 · External reference
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
10.1038/nm.3838 · 2015 · External reference
Biology of GD2 ganglioside: implications for cancer immunotherapy
10.3389/fphar.2023.1249929 · 2023 · External reference
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
10.1038/s41591-023-02612-0 · 2023 · External reference
Tuning the antigen density requirement for CAR T-cell activity
10.1158/2159-8290.cd-19-0945 · 2020 · External reference
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
10.1038/s41586-024-08171-9 · 2025 · External reference
Progressive plasticity during colorectal cancer metastasis
10.1038/s41586-024-08150-0 · 2025 · External reference
Increased carcinoembryonic antigen expression on the surface of lung cancer cells using gold nanoparticles during radiotherapy
10.1016/j.ejmp.2020.06.024 · 2020 · External reference
Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy
10.3389/fonc.2020.01000 · 2020 · External reference
Oncofetal reprogramming: a new frontier in cancer therapy resistance
10.3390/ijtm6010006 · 2026 · External reference
GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts
10.1016/j.omton.2025.201067 · 2025 · External reference
Glypican-2 defines age-dependent axonal response to chondroitin sulfate
10.1016/j.expneurol.2023.114444 · 2023 · External reference
Preclinical assessment of CAR T-Cell therapy targeting the tumor antigen 5T4 in ovarian cancer
10.1097/cji.0000000000000203 · 2018 · External reference
Unraveling Glypican-3: from structural to pathophysiological roles and mechanisms—an integrative perspective
10.3390/cells14100726 · 2025 · External reference
Combined effects of 5-Fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human Colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy
10.1186/1756-9966-27-5 · 2008 · External reference
CAR-T plus radiotherapy: a promising combination for immunosuppressive tumors
10.3389/fimmu.2021.813832 · 2022 · External reference
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
10.1126/science.aay5967 · 2020 · External reference
A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo
10.1126/scitranslmed.abm0306 · 2022 · External reference
The chimeric antigen receptor T cell target claudin 6 is a marker for early organ-specific epithelial progenitors and is expressed in some pediatric solid tumor entities
10.3390/cancers17060920 · 2025 · External reference
Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression
10.1038/s41467-024-47649-y · 2024 · External reference
Chimeric antigen Receptor-Glypican-3 T-Cell therapy for advanced hepatocellular carcinoma: results of phase I trials
10.1158/1078-0432.ccr-19-3259 · 2020 · External reference
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
10.1016/j.omto.2023.04.003 · 2023 · External reference
Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer
10.1016/j.omto.2021.01.002 · 2021 · External reference
Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo
10.1093/protein/gzl033 · 2006 · External reference
Immunohistological distribution of 5T4 antigen in normal and malignant tissues
10.1038/bjc.1990.20 · 1990 · External reference
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
10.1038/s41591-021-01436-0 · 2021 · External reference
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
10.1038/s41586-024-08261-8 · 2025 · External reference
5T4 oncofoetal antigen: an attractive target for immune intervention in cancer
10.1007/s00262-016-1917-3 · 2017 · External reference
The tight-junction protein claudin-6 induces epithelial differentiation from mouse F9 and embryonic stem cells
10.1371/journal.pone.0075106 · 2013 · External reference
Advances and perspectives in CEA-Targeted therapies: from classic biomarker toward actionable therapeutic target
10.1016/j.medj.2025.100986 · 2026 · External reference
CAR-T therapy targets Extra domain B of fibronectin positive solid tumor cells
10.1080/08820139.2023.2264332 · 2023 · External reference
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-Specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
10.1007/s00262-017-2034-7 · 2017 · External reference
Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3
1986 · External reference
Antitumor effects of CAR T cells redirected to the EDB splice variant of fibronectin
10.1158/2326-6066.cir-20-0280 · 2021 · External reference
The expression, regulation, and biomarker potential of Glypican-1 in cancer
10.3389/fonc.2019.00614 · 2019 · External reference
Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death
10.1016/j.ymthe.2022.12.009 · 2023 · External reference
The role of tenascin-C in tumor microenvironments and its potential as a therapeutic target
10.3389/fcell.2025.1554312 · 2025 · External reference
ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice
10.1016/j.xcrm.2025.102400 · 2025 · External reference
IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors
10.1136/jitc-2024-009743 · 2024 · External reference
Therapeutic potential of CLDN family proteins in ovarian cancer: emerging biomarkers and targets
10.31083/fbl45244 · 2025 · External reference
T-Cell tolerance: central and peripheral
10.1101/cshperspect.a006957 · 2012 · External reference
Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment
10.3389/fimmu.2025.1643941 · 2025 · External reference
Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers
10.1016/j.ymthe.2017.03.010 · 2017 · External reference
5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors
2007 · External reference
Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma
10.3389/fonc.2022.824208 · 2022 · External reference
Exploring the mechanism of fibronectin Extra domain B in the tumor microenvironment and implications for targeted immunotherapy and diagnostics
10.3892/mmr.2025.13525 · 2025 · External reference
Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells
10.1038/s41392-026-02780-8 · 2026 · External reference
